🔗 Share this article

Given that the United States undertakes sweeping adjustments to its vaccine guidelines, one figure has emerged in a surprising turn: Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on Covid vaccines in the pandemic and has focused upon alleged fatalities after COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Vaccine Program

Health officials were set to announce major revisions to the pediatric immunization program recently, bringing the US with the Danish national calendar, sources say – a major change that would put the US out of alignment with much of the international standard with no evidence for improved outcomes. The planned update has been postponed until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to present at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to head the division this calendar year.

Consolidating Power at the Regulatory Body

This interim role may indicate a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad solidify control at the FDA – and it points to a renewed priority upon dismantling previously authorized immunizations at the FDA.

Høeg has frequently advocated for discontinuing some childhood shot schedules in the US so as to align more in line with the Danish model, a society with nationalized medicine and a population roughly the size of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on immunizations – typically the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

Dr. Høeg has little discernible experience in medication creation, oversight or administrative roles, which has been typical for past leaders of the biologics center. She has served at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She appears not to have the requisite experience” for overseeing the CDER, stated Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in leading a major agency. She lacks background in industry regulation.”

Former directors of the center would “understand regulatory frameworks and the science of pharmaceutical innovation”, commented a former acting FDA commissioner. “Objectively, she has not acquired the kind of background that former directors who ran the center have had.”

This division has an immense workload at the FDA, she emphasized.

“The public just focuses on the novel medication approvals, but the generic drug division approves a multitude of generic drugs. There’s a biosimilars program, over-the-counter program and so forth, and every single one have to be looked after,” she explained. “The area you overlook, that is the part that I always told people is going to cause problems.”

There is also, a significant management aspect to the position, which manages more than 5,000 staff members. “It is a enormous management job, if you execute it properly,” Woodcock concluded.

Agency Reaction and Disputed Policies

In response to inquiries about Høeg’s credentials and whether this selection represents greater collaboration among regulatory chiefs on immunizations, a representative said that the “concerns stem from flawed assumptions”.

“This background matches the responsibilities of her role,” the spokesperson explained, noting the months Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg inherits the agency head's new expedited review system, a contentious one-day drug-approval program that allegedly troubled her predecessors. “How are these drugs being selected for this voucher program? Who takes the calls?” Dr. Howard questioned. “There is a lot of confidentiality going on at the agency right now.”

In general, he said, “the FDA seems to be moving towards less stringent oversight of most medications, aside from immunizations.”

Public Track Record on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if troubling, past, Howard observe. She released a research paper using non-validated public submissions to estimate the incidence of myocarditis after Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to imply COVID-19 vaccinations are pose a greater threat than they are.

Among her “desired changes” for the incoming administration included revising rules for new vaccines and ending “optional” immunizations, she stated after the election on a podcast. At the FDA, Dr. Høeg has allegedly suggested barring adolescent males from receiving COVID-19 vaccines.

“She is an complete dogmatist who commences with her beliefs and reverse-engineers to fit the science in a extremely deceptive, dishonest way,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of fellow contrarians, {like|